Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002432533 | SCV002727231 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-07-11 | criteria provided, single submitter | clinical testing | The p.P719L variant (also known as c.2156C>T), located in coding exon 12 of the ALK gene, results from a C to T substitution at nucleotide position 2156. The proline at codon 719 is replaced by leucine, an amino acid with similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV003098671 | SCV003476069 | uncertain significance | Neuroblastoma, susceptibility to, 3 | 2022-06-14 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 719 of the ALK protein (p.Pro719Leu). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with ALK-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |